219 related articles for article (PubMed ID: 8698055)
21. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M
J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629
[TBL] [Abstract][Full Text] [Related]
22. Differentiating benign from malignant lung lesions using "quantitative" parameters of FDG PET images.
Hübner KF; Buonocore E; Gould HR; Thie J; Smith GT; Stephens S; Dickey J
Clin Nucl Med; 1996 Dec; 21(12):941-9. PubMed ID: 8957608
[TBL] [Abstract][Full Text] [Related]
23. Test-Retest Variability in Lesion SUV and Lesion SUR in
Hofheinz F; Apostolova I; Oehme L; Kotzerke J; van den Hoff J
J Nucl Med; 2017 Nov; 58(11):1770-1775. PubMed ID: 28473598
[TBL] [Abstract][Full Text] [Related]
24. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation.
Stollfuss JC; Glatting G; Friess H; Kocher F; Berger HG; Reske SN
Radiology; 1995 May; 195(2):339-44. PubMed ID: 7724750
[TBL] [Abstract][Full Text] [Related]
25. Comparison of tumor volumes derived from glucose metabolic rate maps and SUV maps in dynamic 18F-FDG PET.
Visser EP; Philippens ME; Kienhorst L; Kaanders JH; Corstens FH; de Geus-Oei LF; Oyen WJ
J Nucl Med; 2008 Jun; 49(6):892-8. PubMed ID: 18483085
[TBL] [Abstract][Full Text] [Related]
26. Lung tumor metastasis to breast detected by fluorine-18-fluorodeoxyglucose PET.
Hunter GJ; Choi NC; McLoud TC; Fischman AJ
J Nucl Med; 1993 Sep; 34(9):1571-3. PubMed ID: 8394885
[TBL] [Abstract][Full Text] [Related]
27. Predictive value of 18F-fluorodeoxyglucose uptake by positron emission tomography for non-small cell lung cancer patients treated with radical radiotherapy.
Ikushima H; Dong L; Erasmus J; Allen P; McAleer MF; Zhuang Y; Sasaki R; Komaki R
J Radiat Res; 2010; 51(4):465-71. PubMed ID: 20508373
[TBL] [Abstract][Full Text] [Related]
28. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).
Duhaylongsod FG; Lowe VJ; Patz EF; Vaughn AL; Coleman RE; Wolfe WG
J Thorac Cardiovasc Surg; 1995 Jul; 110(1):130-9; discussion 139-40. PubMed ID: 7609536
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Positron Emission Tomography Using 2-[18F]-fluoro-2-deoxy-D-glucose and 3-deoxy-3-[18F]-fluorothymidine in Lung Cancer Imaging.
Wang FL; Tan YY; Gu XM; Li TR; Lu GM; Liu G; Huo TL
Chin Med J (Engl); 2016 Dec; 129(24):2926-2935. PubMed ID: 27958224
[TBL] [Abstract][Full Text] [Related]
30. 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma.
Hoffmann M; Vogelsang H; Kletter K; Zettinig G; Chott A; Raderer M
Gut; 2003 Mar; 52(3):347-51. PubMed ID: 12584214
[TBL] [Abstract][Full Text] [Related]
31. Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients.
Kramer GM; Frings V; Hoetjes N; Hoekstra OS; Smit EF; de Langen AJ; Boellaard R
J Nucl Med; 2016 Sep; 57(9):1343-9. PubMed ID: 27103020
[TBL] [Abstract][Full Text] [Related]
32. Is 18F-3'-fluoro-3'-deoxy-L-thymidine useful for the staging and restaging of non-small cell lung cancer?
Cobben DC; Elsinga PH; Hoekstra HJ; Suurmeijer AJ; Vaalburg W; Maas B; Jager PL; Groen HM
J Nucl Med; 2004 Oct; 45(10):1677-82. PubMed ID: 15471832
[TBL] [Abstract][Full Text] [Related]
33. 18F-FLT PET for visualization of laryngeal cancer: comparison with 18F-FDG PET.
Cobben DC; van der Laan BF; Maas B; Vaalburg W; Suurmeijer AJ; Hoekstra HJ; Jager PL; Elsinga PH
J Nucl Med; 2004 Feb; 45(2):226-31. PubMed ID: 14960640
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
35. Correlation of PET standard uptake value and CT window-level thresholds for target delineation in CT-based radiation treatment planning.
Hong R; Halama J; Bova D; Sethi A; Emami B
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):720-6. PubMed ID: 17293230
[TBL] [Abstract][Full Text] [Related]
36. Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in lymph node metastases of non-small cell lung cancer (NSCLC) patients using hybrid 18F-FDG PET/MRI.
Schaarschmidt BM; Buchbender C; Nensa F; Grueneisen J; Gomez B; Köhler J; Reis H; Ruhlmann V; Umutlu L; Heusch P
PLoS One; 2015; 10(1):e0116277. PubMed ID: 25574968
[TBL] [Abstract][Full Text] [Related]
37. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET.
Minn H; Zasadny KR; Quint LE; Wahl RL
Radiology; 1995 Jul; 196(1):167-73. PubMed ID: 7784562
[TBL] [Abstract][Full Text] [Related]
38. Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues.
Paquet N; Albert A; Foidart J; Hustinx R
J Nucl Med; 2004 May; 45(5):784-8. PubMed ID: 15136627
[TBL] [Abstract][Full Text] [Related]
39. Variation in background intensity affects PET-based gross tumor volume delineation in non-small-cell lung cancer: the need for individualized information.
Chen GH; Yao ZF; Fan XW; Zhang YJ; Gao HQ; Qian W; Wu KL; Jiang GL
Radiother Oncol; 2013 Oct; 109(1):71-6. PubMed ID: 24060171
[TBL] [Abstract][Full Text] [Related]
40. Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas.
Nakamoto Y; Higashi T; Sakahara H; Tamaki N; Kogire M; Doi R; Hosotani R; Imamura M; Konishi J
Cancer; 2000 Dec; 89(12):2547-54. PubMed ID: 11135214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
